OncoMatch/Clinical Trials/NCT05352178
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Is NCT05352178 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Androgen deprivation therapy and Androgen receptor targeted therapy for prostate cancer.
Treatment: Androgen deprivation therapy · Androgen receptor targeted therapy — The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
WHO 0–2
Prior therapy
Must have received: radical prostatectomy
radical prostatectomy
Must have received: postoperative radiotherapy
postoperative radiotherapy
Cannot have received: LHRH agonist
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: LHRH antagonist
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: antiandrogen
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: maximal androgen blockade
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: oestrogen
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify